Aung Naing

Aung Naing is a Senior Professor at The University of Texas MD Anderson Cancer Center, specializing in oncology and cancer immunotherapy. His research focuses on early-phase clinical trials, novel immunotherapeutic combinations, and rare tumor treatments, with particular emphasis on immune checkpoint blockade, ICOS and TIGIT pathway modulation, and NLRP3 agonists. His pioneering work includes phase I/II trials of agents such as BMS-986299, M6223, and PF-07209960, and the DART protocol investigating dual anti-CTLA-4 and anti-PD-1 therapy. His recent findings in advanced NSCLC, vaginal cancer, and endometrial cancer have appeared in venues such as npj Precision Oncology, Gynecologic Oncology, and the Journal for ImmunoTherapy of Cancer.